Table 4.
Description of antimicrobial resistance profiles of novel lactic acid bacteria (LAB) strains.
| No. of antimicrobial resistance phenotypes observeda | Strain ID | Fluoroquinolone | Lipopeptide | Tetracycline | Glycopeptide | Folate pathway inhibitor | Lincosamide | Spectrogramin | Rifamycin | Aminoglycoside |
|---|---|---|---|---|---|---|---|---|---|---|
| J16 | LVX | |||||||||
| 1 | L5-B | LVX | ||||||||
| L6-B | LVX | |||||||||
| L28 | TET | VAN | ||||||||
| L20-B | LVX | DAP | ||||||||
| J7 | LVX | DAP | ||||||||
| J14 | LVX | DAP | ||||||||
| J27 | LVX | DAP | ||||||||
| J43 | LVX | DAP | ||||||||
| 2 | J34 | LVX | DAP | |||||||
| J25 | LVX | DAP | ||||||||
| L5-A | LVX | DAP | ||||||||
| J19 | LVX | DAP | ||||||||
| L30 | TET | CLI | ||||||||
| L10 | CLI | SYN | ||||||||
| L14-A | CLI | SYN | ||||||||
| L9 | CLI | SYN | ||||||||
| L3-A | VAN | SXT | ||||||||
| L8-A | VAN | SXT | ||||||||
| L14-C | LVX | VAN | SXT | |||||||
| L15 | LVX | VAN | SXT | |||||||
| 3 | L14-B | LVX | VAN | SXT | ||||||
| L2-A | LVX | VAN | SXT | |||||||
| L4-B | LVX | CLI | RIF | |||||||
| L24-B | DAP | TET | CLI | SYN | ||||||
| >3 | L22 | DAP | TET | CLI | SYN | |||||
| L24-A | DAP | TET | CLI | SYN | ||||||
| L25 | DAP | TET | CLI | SYN | GEN |
aDAP, daptomicyn; LVX, levofloxacin; TET, tetracycline; VAN, vancomycin; STX, trimethoprim-sulphamethoxazole; CLI, clindamycin; SYN, synercid; RIF, rifampicin; GEN, gentamicin.